Netherton Syndrome
Conditions
Keywords
Netherton Syndrome, DS-2325a, Healthy Participants
Brief summary
Netherton syndrome (NS) is a rare autosomal recessive disease and no systemic treatment or standard of care currently exists for patients with NS. DS-2325a, a specific and potent inhibitor of kallikrein 5, is expected to treat NS by replacing a defective gene.
Detailed description
This first-in-human study for DS-2325a will evaluate the safety, tolerability, and pharmacokinetics of single ascending doses of DS-2325a in healthy participants. DS-2325a will be evaluated after both subcutaneous (SC) injections and intravenous (IV) infusions, as it may have to be given intravenously to young patients and as loading dose.
Interventions
DRUGDS-2325a
Subcutaneous injection (starting dose 30 mg)
DRUGPlacebo
Subcutaneous injection
Sponsors
Daiichi Sankyo
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Participants must give written informed consent to participation in the study prior to Screening * Healthy men and women 18 to 45 years of age (inclusive), with a BMI of 18 kg/m2 to 30 kg/m\^2 (inclusive) at Screening * All women must have a negative serum pregnancy test at Screening and all women of childbearing potential must have a negative urine pregnancy test on Day -1 * Women must not be lactating during the study treatment period and for 3 months after the last dose of study treatment * Women of childbearing potential must practice effective contraception during the study treatment period and for 3 months after the last dose of study treatment. They must agree to use 2 different means of nonhormonal contraceptive methods * Women of non-childbearing potential must be either surgically sterile (ie, bilateral tubal ligation at least 3 months prior to dosing) or in menopausal state confirmed as follows: 1 year of spontaneous amenorrhea without an alternative medical cause and a serum FSH level ≥40 mIU/mL * Men must agree to use contraception (condom with spermicide) during the study treatment period and for at least 3 months after the last dose of study treatment or be surgically sterile (vasectomy at least 3 months prior to dosing) * Women should not donate eggs and men should not donate sperm during the study treatment period and for at least 3 months after the last dose of study treatment * Participants must be in good health as determined by Screening medical history, physical examination, vital signs, ECGs, serum chemistry, hematology, virology, and urinalysis performed at Screening and on Day -1
Exclusion criteria
* History or current chronic lung disease including asthma, chronic obstructive pulmonary disease (COPD), or heavy smoking of \>10 pack years * Previous or current treatment with systemic corticosteroids or any immunosuppressive agents * Participants who have received a transfusion or any blood products within the last year prior to dosing * Participants who have made any blood donation or have had a loss of blood of ≥500 mL within 56 days prior to the dose of study drug * Participants who consume more than 21 units of alcohol per week (1 unit of alcohol equals 1/2 pint of beer, 4 ounces of wine, or 1 ounce of spirits) or those participants who have a significant history of alcoholism or drug/chemical abuse within the last 2 years. * Participants with positive results on tests for drugs of abuse, cotinine, or alcohol at Screening and/or Day -1.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants with Any Treatment-emergent Adverse Events Following Administration of DS-2325a | Screening (Day -28 to -3) pre-dose up to Day 57 post-dose | Treatment-emergent adverse events (TEAEs) are defined as new adverse events (AEs) that occur after the dose of study drug or as AEs that were present prior to the dose of study drug but which worsened in severity after the start of study drug. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetic Parameter Time to Maximum Concentration (Tmax) | SC and IV cohorts: Day 1 pre-dose and 1, 2, 4, 8 hours (hr) post-dose; 24, 48, 96, 120, 144, 168, 192, 240, 288, 336, 384, 432, 480, 552, 624, 696, 768, 840, 1008, 1176, 1344 hr post-dose | Pharmacokinetic parameters will be calculated for DS-2325a by noncompartmental methods. |
| Pharmacokinetic Parameter Maximum Concentration (Cmax) | SC and IV cohorts: Day 1 pre-dose and 1, 2, 4, 8 hours (hr) post-dose; 24, 48, 96, 120, 144, 168, 192, 240, 288, 336, 384, 432, 480, 552, 624, 696, 768, 840, 1008, 1176, 1344 hr post-dose | Pharmacokinetic parameters will be calculated for DS-2325a by noncompartmental methods. |
| Pharmacokinetic Parameter Last Measurable Time (Tlast) | SC and IV cohorts: Day 1 pre-dose and 1, 2, 4, 8 hours (hr) post-dose; 24, 48, 96, 120, 144, 168, 192, 240, 288, 336, 384, 432, 480, 552, 624, 696, 768, 840, 1008, 1176, 1344 hr post-dose | Pharmacokinetic parameters will be calculated for DS-2325a by noncompartmental methods. |
| Pharmacokinetic Parameter Area Under the Concentration Curve (AUC) | SC and IV cohorts: Day 1 pre-dose and 1, 2, 4, 8 hours (hr) post-dose; 24, 48, 96, 120, 144, 168, 192, 240, 288, 336, 384, 432, 480, 552, 624, 696, 768, 840, 1008, 1176, 1344 hr post-dose | Pharmacokinetic parameters will be calculated for DS-2325a by noncompartmental methods. |
| Pharmacokinetic Parameter Elimination Half-life (T1/2) | SC and IV cohorts: Day 1 pre-dose and 1, 2, 4, 8 hours (hr) post-dose; 24, 48, 96, 120, 144, 168, 192, 240, 288, 336, 384, 432, 480, 552, 624, 696, 768, 840, 1008, 1176, 1344 hr post-dose | Pharmacokinetic parameters will be calculated for DS-2325a by noncompartmental methods. |
| Number of Participants Who Are Anti-Drug Antibody (ADA)-Positive (Baseline and Post-Baseline) and Number of Participants Who Have Treatment-emergent ADA | Day 1 pre-dose and 336 hours (hr), 552 hrs, 696 hrs, and 1344 hrs post-dose | Blood samples will be collected to determine ADAs. |
| Pharmacokinetic Parameter Elimination Rate Constant Associated With the Terminal Phase (Kel) | SC and IV cohorts: Day 1 pre-dose and 1, 2, 4, 8 hours (hr) post-dose; 24, 48, 96, 120, 144, 168, 192, 240, 288, 336, 384, 432, 480, 552, 624, 696, 768, 840, 1008, 1176, 1344 hr post-dose | Pharmacokinetic parameters will be calculated for DS-2325a by noncompartmental methods. |
Countries
United States
Outcome results
None listed